Global Immuno-Oncology (IO) Market – Industry Trends and Forecast to 2030

Global Immuno-Oncology (IO) Market, By Type (Immune Cell Therapy (CAR-T), Monoclonal Antibodies, Checkpoint Inhibitors, Cytokines, Cancer Vaccines, Others), Targets (IDO1i, oncolytic virus, STING agonist, TLR agonist, TIL, MEKi, TIGIT, CPI, GITR agonist, TGF-b trap, A2AR antagonist/CD73i, LAG-3, anti-CTLA-4, MAGE-A3, VEGF, HDAC, STING, TIM-3, TGF-Beta, OX40, Others), Indication (Malignant Tumors, Benign Tumors, Others), End Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) – Industry Trends and Forecast to 2030.

Immuno-Oncology (IO) Market Analysis and Size

Government approval for cytokines, vaccines, tumor-directed monoclonal antibodies, immune checkpoint blockers, and other IO medications has contributed to substantial advancements in IO in recent years. The market is anticipated to increase as more people become aware of the benefits of IO over traditional approaches. In contrast to merely treating cancer, IO therapies stimulate the immune system, which helps to address a larger patient population. This will open up new potential for the industry's expansion throughout the forecast period.

Data Bridge Market Research analyses that the immuno-oncology (IO) market, which is USD 28.10 billion in 2022, is expected to reach USD 156.05 billion by 2030, at a CAGR of 23.9% during the forecast period 2023 to 2030. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Immuno-Oncology (IO) Market Scope and Segmentation  

Market Definition

Immuno-Oncology (I-O) is an advanced area of research that seeks to help the body's immune system fight cancer. Drugs used for cancer treatment enhance or suppress the immune system to support the body's defenses against cancer, infections, and other diseases. To boost the immune system and help the body find and get rid of cancer cells, it uses substances created by the body or in a lab.

Immuno-Oncology (IO) Market Dynamics

Drivers

• The rise in cancer cases will bolster the market growth

The market for immuno-oncology drugs is projected to expand due to the increase in cancer diagnoses worldwide. For instance, the American Cancer Society predicts that there will be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US in January 2022, or about 1,670 fatalities every day. Lung, prostate, bowel, and female breast cancer are the top four cancer types globally, making up 43% of all new cancer cases. Lung, prostate, bowel, and female breast cancer account for 43% of all new instances of cancer, making them the four most prevalent cancers worldwide. Therefore, it is projected that the rise in cancer incidence rates worldwide will increase the demand for immune-oncology medications.

• Rising research and development funding will propel the market growth

Research and development funding is heavily invested in the fight against cancer, particularly precision medicine. Based on a person's genetic profile, precision medicine offers them individualized care. Consequently, the future of cancer treatment is likely to involve a combination of immunotherapy and personalized therapy. Better patient outcomes will surely be observed across a wide range of cancer types due to the advances in cancer management backed by the most recent surgical and radiation technology. These are the certain factors that propel the market growth.

Opportunities

• Collaboration and partnerships are a promising opportunity

Companies have long collaborated with academic and research organizations in this industry for a long time through partnerships and in- or out-licensing agreements, and this trend has been accelerating in recent years. For instance, in September 2020, the US-based biopharmaceutical company AbbVie, Inc., which specializes in drug discovery, research, and development, announced its research partnership with I-Mab Biopharma Co. Ltd. This Chinese biopharmaceutical company has made significant advancements in the discovery, development, and commercialization of biological drugs for immunology. Together, the two companies will focus on developing Lemzoparlimab (also known as TJC4), a novel anti-CD47 monoclonal antibody that I-Mab separately discovered and developed to treat a variety of malignancies. The agreement covers its commercialization and development. Additionally, the two parties could opt to continue working together.

Restraints/Challenges

• Serious problems with high medical expenses will hamper the market growth

Patients around the world have a serious problem with high medical expenses. There is a lot of pressure to keep expenses down and show value. The absence of affordable medications has affected the health of the populace in less developed countries and contributed to a short average life expectancy. Immunotherapy frequently carries an average annual cost of more than $100,000 per patient, which would increase to $850,000 per patient if the value of medical aid were considered. As a result, it is anticipated that the market for immuno-oncology drugs will experience slow growth due to the high cost of immuno-oncology therapy.

This immuno-oncology (IO) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the immuno-oncology (IO) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

• In 2021, Amunix Pharmaceuticals, Inc. was acquired by Sanofi SA, a biopharmaceutical and healthcare organization with its headquarters in France, for $1 billion. With the help of this acquisition, Sanofi is better able to develop novel treatments for cancer patients, conduct research on immune-oncology therapeutic candidates, find new drugs, bring these potentially better and safer treatment options to patients by collaborating as a center of excellence, and expand its oncology pipeline.

Global Immuno-Oncology (IO) Market Scope

The immuno-oncology (IO) market is segmented on the basis of type, target, indication, end users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Immune Cell Therapy (CAR-T)
• Monoclonal Antibodies
• Checkpoint Inhibitors
• Cytokines
• Cancer Vaccines
• Others

 Targets

• IDO1i
• Oncolytic virus
• STING agonist
• TLR agonist
• TIL
• MEKi
• TIGIT
• CPI
• GITR agonist
• TGF-b trap
• A2AR antagonist/CD73i
• LAG-3
• Anti-CTLA-4
• MAGE-A3, VEGF
• HDAC
• STING
• TIM-3
• TGF-Beta
• OX40
• Others

 Indication

• Malignant Tumors
• Benign Tumors
• Others

 End Users

• Hospitals
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others

Immuno-Oncology (IO) Market Regional Analysis/Insights

The immuno-oncology (IO) market is analysed and market size insights and trends are provided by country, type, target, indication, end users and distribution channel as referenced above.

The countries covered in the immuno-oncology (IO) market report are U.S., Canada, and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the immuno-oncology (IO) market as a result of the disease's rising occurrence. The region's immuno-oncology (IO) market will also experience increased expansion due to the expanding accessibility of contemporary therapies.

Asia-Pacific is expected to grow at the highest growth rate in the forecast period of 2023 to 2030 owing to the uptake of cancer immunotherapy is expanding at a good rate. Additionally, it is expected that the immuno-oncology (IO) market will develop in the region in the upcoming years due to the rise in disease incidence and, consequently, the rising death rate.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Competitive Landscape and Immuno-Oncology (IO) Market Share Analysis

The immuno-oncology (IO) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to immuno-oncology (IO) market.

Some of the major players operating in the immuno-oncology (IO) market are:

• Bristol Myers Squibb Company (US.)
• Novartis AG (Switzerland)
• F. Hoffmann-LA Roche Ltd. (Switzerland)
• Merck & Co., Inc. (U.S.)
• GSK Plc. (UK.)
• Eli Lilly and Company (US.)
• Fresenius Kabi AG (Germany)
• Pfizer Inc. (US.)
• AbbVie Inc. (US.)
• Genentech Inc. (U.S.)
• Sanofi (France)
• AstraZeneca (UK.)